Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with a confirmed diagnosis of a specific blood cancer called B-precursor B-ALL, or a type of lymphoma called DLBCL or Burkitt lymphoma, as classified by the World Health Organization (WHO).
• People with a confirmed diagnosis of neuroblastoma (a type of nerve tissue cancer) or Ewing sarcoma (a type of bone and soft tissue cancer).

Who may not be able to join:

• People who have previously had a solid organ transplant (such as a kidney, liver, or heart transplant).
• People with a significant, currently active heart or blood vessel disease.
• People with a known history of liver cirrhosis (severe liver scarring).
• People who currently have moderate or severe nerve damage causing symptoms such as numbness or tingling (Grade 2 or higher peripheral neuropathy).
• People diagnosed with a specific inherited nerve condition called the demyelinating form of Charcot-Marie-Tooth disease.
• People who have been diagnosed with Down syndrome.
• People who are currently experiencing graft-versus-host disease (a complication that can follow a stem cell or bone marrow transplant) at any level of severity, or who are receiving treatment or preventive medication for it.
• People with a known history of HIV infection.
• People who have a known allergy or medical reason preventing them from receiving the study treatment or any of its ingredients.
• People who have received radiation therapy within the 4 weeks before the trial starts, or who have not yet fully recovered from side effects of radiation.
• People who are taking ongoing daily steroid medication (corticosteroids) at a dose higher than the equivalent of 10 mg of prednisone per day, unless that dose has been stable for at least 4 weeks before starting the trial.
• People who have taken certain strong medications that affect how the body processes other drugs (strong CYP3A4 inhibitors within the past 7 days, or strong CYP3A4 inducers within the past 14 days), or who are expected to need these medications during or for 30 days after the trial treatment (confirm with trial site).
• People who have received other systemic cancer treatments or experimental therapies within 4 weeks before the first trial dose (with some specific exceptions — confirm with trial site).
• People who have received a live or live-attenuated vaccine within 30 days before the first trial dose.
• People who have received another experimental treatment or used an experimental medical device within 4 weeks before starting the trial.
• People who have another cancer that is currently growing or has required active treatment within the past year.
• People who currently have an active infection that requires systemic treatment (such as antibiotics given by mouth or through a drip).
• People with a known history of Hepatitis B, or a currently active Hepatitis C infection.
• People who have not fully recovered from major surgery, or who have ongoing complications from a recent surgery.

Important: Always verify eligibility with the trial site directly before applying.